Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT01545102
Other study ID # TN11-26
Secondary ID
Status Not yet recruiting
Phase N/A
First received February 29, 2012
Last updated March 6, 2012
Start date April 2012
Est. completion date April 2013

Study information

Verified date March 2012
Source Eastbourne General Hospital
Contact Jet van Zalen, MSc, BSc
Phone 01323417400
Email jet.vanzalen@esht.nhs.uk
Is FDA regulated No
Health authority United Kingdom: National Health ServiceUnited Kingdom: Research Ethics Committee
Study type Observational

Clinical Trial Summary

Cardiac rehabilitation is the ideal comprehensive intervention for patients with chronic heart failure (CHF), since it addresses the complex interplay of medical, psychological and behavioural factors facing these individuals. Structured exercise training within a cardiac rehabilitation programme is firmly recommended for these patients. However, it is questionable whether patients are achieving an adequate dose of exercise to provide optimal benefits. The essential components for setting optimal training include the appropriate mode, duration, frequency and intensity of exercise. UK surveys of cardiac rehabilitation describe the frequency and duration of training, but here is scant information on exercise intensity. However, it is apparent that randomised controlled trials of exercise training use doses more than 4 times greater than in UK current practice. The Eastbourne Exercise Cardiology Research Group has demonstrated that although patients benefit from improved quality of life and submaximal fitness after a hospital outpatient cardiac rehabilitation programme, they do not achieve the increases in important prognostic indicators reported by the majority of exercise training trials.

The critical factor in terms of eliciting a sufficient training effect while minimising risk is the intensity of the exercise performed. It is now widely accepted that the traditional methods of using fixed percentages of maximal heart rate or oxygen uptake to set exercise intensity include serious errors. The European Society of Cardiology recommends that cardiopulmonary exercise testing should be used to provide an objective evaluation of the metabolic demand of exercise. This allows physiologically meaningful reference points to be established for aerobic exercise prescription and is the solution to defining safe and effective training intensities. The next step is to determine whether this information can be transferred to a practical cardiac rehabilitation environment to set and monitor exercise intensity


Description:

Background Heart failure is a chronic, costly and life-threatening disorder that constitutes a significant burden for individuals and the National Health Service [There are 27,000 new cases reported per annum in the UK. Cardiac rehabilitation (CR) is recommended as the ideal comprehensive intervention since it addresses the complex interplay of medical, psychological and behavioural factors facing CHF patients and carers.

Study Aim Primary objective to describe the exercise intensity, defined by oxygen uptake (VO2) in terms of the individual physiological thresholds, in CHF patients undergoing CR according to current guidelines Primary end point: VO2 Secondary objectives Secondary objectives of this study are:-

1. To measure resting and exercising energy expenditure in order to a) establish the value of 1 MET (resting metabolic rate) for patients with CHF, and b) to establish the MET value (defined as multiples of resting metabolic rate) for exercises performed in CR sessions

2. To measure affective responses (feeling very bad - feeling very good; levels of energy - tiredness and tension - calmness) to exercise during CR sessions

3. To measure weekly physical activity level in CHF patients undergoing Phase III and IV CR.

For the secondary analysis the following secondary end points and parameters will be established

1. MET values, defined as multiples of resting oxygen uptake or resting metabolic rate (1 MET), for different CR exercises

2. Ratings of affective response on the Feelings Scale (FS) and ratings of perceived activation on the Felt Arousal Scale (FAS).

3. Average daily activity over 7 day period in terms of steps per day and periods spent sitting, standing and walking


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 21
Est. completion date April 2013
Est. primary completion date April 2013
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion criteria:

- Systolic heart failure with resting left ventricular ejection fraction below 40%

- New York Heart Association (NYHA) class I-III

- clinically stable for at least 4 weeks on optimised medication dosage according to current guidelines

Exclusion criteria:

- Acute coronary syndrome within past 6 months

- Untreated lifethreatening cardiac arrhythmias

- Acute heart failure (during initial period of haemodynamic instability)

- Uncontrolled hypertension

- Advanced atrioventricular block

- Acute myocarditis or pericarditis

- Symptomatic aortic stenosis

- Severe hypertrophic obstructive cardiomyopathy

- Acute systemic illness Intracardiac thrombus

- Progressive worsening of exercise tolerance of dyspnoea at rest over previous 35 days

- Significant ischaemia during low intensity exercise (< 2 METS, < 50W)

- Uncontrolled diabetes

- Recent embolism

- Thrombophlebitis

- New onset atrial fibrillation/flutter

- > 1.8 kg increase in body mass over previous 13 days

- Concurrent, continuous or intermittent dobutamine therapy

- Decrease in systolic blood pressure with exercise

- NYHA Functional Class IV

- Complex ventricular arrhythmia at rest or appearing with exertion

- Supine resting heart rate > 100 beats/min

- Patient is participating in a conflicting study, is unable to perform exercise testing

- Patient lacks the capacity to consent or cannot comply with study requirements

Study Design

Observational Model: Cohort, Time Perspective: Prospective


Related Conditions & MeSH terms


Locations

Country Name City State
United Kingdom Eastbourne General Hospital Eastbourne East Sussex

Sponsors (1)

Lead Sponsor Collaborator
Guy Lloyd

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary The primary outcome measure is the oxygen uptake(VO2)during exercise 13 weeks No
Secondary Affective responses (e.g. feelings of pleasure/displeasure) Questionnaire used to measure affective responses (Feelings Scale, Felt Anxiety Scale and Activation/Deactivation ) 13 weeks No
Secondary Weekly physical activity Average daily physical activity: Participants' freeliving activity will be classified by ActivPAL into periods spent sitting, standing and walking, and daily energy expenditure will also be estimated from this information. 13 weeks No
See also
  Status Clinical Trial Phase
Completed NCT03799133 - Safety and Efficacy of the Gastric Reactance (XL) in Patients Post-operated of Elective Cardiac Surgery N/A
Not yet recruiting NCT04538469 - Absent Visitors: The Wider Implications of COVID-19 on Non-COVID Cardiothoracic ICU Patients, Relatives and Staff
Terminated NCT02205411 - Clinical Trial to Evaluate the the ReliantHeart HeartAssist 5® VAD System in Patients Awaiting Heart Transplantation N/A
Completed NCT02524574 - Tomography Positron Emission Assessment of the Impact of Cardiac Rehabilitation on Coronary Endothelial Function in Cardiac Failure N/A
Active, not recruiting NCT03841084 - Blend to Limit Oxygen in ECMO: A Randomised Controlled Registry Trial Phase 2
Terminated NCT02459054 - Syncardia 50cc TAH-t as a Bridge to Transplant N/A
Terminated NCT02859636 - Pronostic Value of Endothelial Dysfunction in Heart Failure N/A
Completed NCT04599816 - Levosimendan Administration in Pulmonary Hypertension N/A
Recruiting NCT05761639 - Physical Exercise and Telephone Follow-up Mediated by Telerehabilitation N/A
Not yet recruiting NCT04696523 - Effect of Xenon on Brain Injury After Aneurysmal Subarachnoid Hemorrhage Phase 2
Completed NCT03357731 - A Study of Continuous Infusions of HNO (Nitroxyl) Donor in Patients With Heart Failure and Impaired Systolic Function Phase 2
Completed NCT02331264 - Cardiac Assessment of Patients With Hip Implants N/A
Terminated NCT01921829 - Protocolized Diuretic Strategy in Cardiorenal Failure Phase 4
Completed NCT06197256 - Cardiac Dysfunction in Critically Ill Covid-19 Patients
Recruiting NCT03197792 - Perioperative Portal Vein Pulsatility as a Postoperative Prognostic Indicator in Pulmonary Endarterectomy N/A
Completed NCT03515980 - An Investigational Study of Experimental Medication BMS-986231 Given in Participants With Different Levels of Liver Function Phase 1
Completed NCT03212898 - Pharmacist Interventions in Rural Elderly Warfarin Patients N/A
Completed NCT03243604 - cARdiotoxicity Profile of aBIraTeRone in prostAte Cancer : a pharmacoviGilancE Study
Completed NCT06330103 - Efficacy of AI EF Screening by Using Smartphone Application Recorded PLAX View Cardiac Ultrasound Video Clips N/A
Completed NCT02660385 - Insomnia Self-Management in Heart Failure N/A